Agents and Actions

, Volume 16, Issue 6, pp 470–477 | Cite as

Histamine-releasing properties of Polysorbate 80in vitro andin vivo: correlation with its hypotensive action in the dog

  • Emanuela Masini
  • Jaques Planchenault
  • Francis Pezziardi
  • Patrick Gautier
  • Jean Pierre Gagnol
Histamine and Kinins

Abstract

The solvent of commercial amiodarone (Polysorbate 80) has been reported to produce haemodynamic responses in humans and in dogs similar to those produced by histamine infusion. We therefore evaluated the correlation between hypotension induced by the solvent of amiodarone and its histamine-releasing properties in the awake dog.

The solvent of amiodarone administered to a dog, over 5 min in a dose of 10 mg/kg of Polysorbate 80, produced severe hypotension after the first administration; the second injection (24 h later) caused fewer hypotensive effects.

Histamine release in the peripheral tissues was demonstrated by a marked increase in plasma histamine concentrations, with the maximum value 10 min after the solvent administration. H1- and H2-receptor blockade with mepyramine (5 mg/kg) and cimetidine (10 mg/kg) significantly reduced the cardiovascular effects of the solvent.

Isolated peritoneal mast cells from rats also released histamine in response to Polysorbate 80. These studies show that Polysorbate 80 releases histamine bothin vitro and in isolated mast cells from rats andin vivo in the dog, and that the plasma concentrations are correlated with the haemodynamic responses.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    M. Alam, G.V. Anrep, G.S. Barsoum, M. Talaat andE. Wieninger,Liberation of histamine from skeletal muscle by curare, J. Physiol., Lond.95, 148–158 (1939).Google Scholar
  2. [2]
    P.L. Smith, A. Kagey-Sobotka, E.R. Bleecker, R. Traystman, A.P. Kaplan, H. Gralnick, M.D. Valentine, S. Permutt andL.M. Lichtenstein,Physiological manifestations of human anaphylaxis, J. clin. Invest.66, 1072–1080 (1980).PubMedGoogle Scholar
  3. [3]
    J. Moss, N. Fahmy, N. Sunder andM.A. Beaven,Hormonal and hemodynamic profile of anaphylactic reaction in man, Circulation63, 210–213 (1981).PubMedGoogle Scholar
  4. [4]
    K. Pavek, A. Wegmann, L. Nordström andD. Schwander,Cardiovascular and respiratory mechanisms in anaphylactic and anaphylactoid shock reactions, Klin. Wschr.60, 941–947 (1982).CrossRefPubMedGoogle Scholar
  5. [5]
    C. Meyer-Burgdorff, G. Seidel andF.J. Schlüter,Freisetzung von Histamin und Serotonin bei extrakorporaler Zirkulation, Anaesthesist22, 212–216 (1973).PubMedGoogle Scholar
  6. [6]
    H.G. Beger andD. Stopix,Histamine release and hepatic elimination of histamine following abdominal surgery, Klin. Wschr.60, 935–938 (1982).CrossRefPubMedGoogle Scholar
  7. [7]
    W. Lorenz, A. Doenicke, B. Schöning andE. Neugebauer, The role of histamine in adverse reactions to intravenous agents. InAdverse Reactions to Anaesthetic Drugs, pp. 169–238 (Ed.J.A. Thornton) Elsevier, North-Holland Biomedical Press, Amsterdam 1981.Google Scholar
  8. [8]
    C. Meyer-Burgdorff, G. Seidel andI. Wolf,Histaminfreistzung durch Narkosemittel, Anaesthesist25, 1–5 (1976).PubMedGoogle Scholar
  9. [9]
    J. Moss, C.D. Rosow, J.J. Savarese, D.M. Philbin andK.F. Kniffen,Role of histamine in the hypotensive action of d-tubocuranine in humans, Anaesthesiology55, 19–25 (1981).Google Scholar
  10. [10]
    D.M. Philbin, J. Moss, C.W. Akins, C.E. Rosow, K.,R.C. Schneider, T.R. Verlee andJ.J. Savarese,The use of H 1-and H 2-histamine antagonists with morphine anaesthesia: a double blind study, Anaesthesiology55, 292–296 (1981).Google Scholar
  11. [11]
    C.E. Rosow, J. Moss, D.M. Philbin andJ.J. Savarese, Histamine release during morphine and fentanyl anesthesia. Anaesthesiology56, 93–96 (1982).Google Scholar
  12. [12]
    S.D., Rockoff andU.T. Aker,Contrast media as histamine liberators: VI. Arterial plasma histamine and hemodynamic responses following angiocardiography in man with 75% hypaque, Invest. Radiol.7, 403–406 (1972).PubMedGoogle Scholar
  13. [13]
    W. Lorenz, A. Doenicke, B. Schöning, C.H. Ohmann, B. Grote andE. Neugebauer,Definition and classification of histamine-release response to drugs in anaesthesia and surgery: studies in the conscious human subject, Klin. Wschr.60, 896–913 (1982).CrossRefPubMedGoogle Scholar
  14. [14]
    M.R. Bristow, W.S. Sageman, R.H. Scott, M.E. Billingham, R.E. Bowder, R.S. Kernoff, G.H. Snidow andJ.R. Daniels,Acute and chronic cardiovascular effects of Doxorubicin in dog: the cardiovascular pharmacology of drug-induced histamine release, J. Cardiovasc. Pharmac.2, 487–515 (1980).Google Scholar
  15. [15]
    A. Eschalier, M. Rodriguez, C. Burtin andJ. Lavarenne,Acute cardiovascular effects of several antitumor agents in the dog: involvement of histamine, Naunyn-Schmiedeberg's Arch. Pharmak. Supplement 324, Abs.256 (1983).Google Scholar
  16. [16]
    W. Lorenz, A. Schmal, H. Schult, S. Lang, C.H. Ohmann, D. Weber, B. Kappa, L. Luben andA. Doenicke,Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components of Cremophor El ® and development of a component with reduced toxicity, Agents and Actions12, 64–81 (1982).CrossRefPubMedGoogle Scholar
  17. [17]
    W. Lorenz, A. Doenicke, R. Meyer, H.J. Reimann, J. Kusche, H. Barth, H. Geesing, M. Hutzel andB. Weissenbacher,Histamine release in man by Propanidid and Thiopentone: pharmacological effects and clinical consequences, Br. J. Anaesth.44, 355–369 (1972).PubMedGoogle Scholar
  18. [18]
    W. Lorenz, A. Doenicke, R. Meyer, H.J. Reimann, J. Kusche, H. Barth, H. Geesing, M. Hutzel andB. Weissenbacher,An improved method for the determination of histamine release in man: its application in studies with propanidid and thiopentone, Eur. J. Pharmac.19, 180–190 (1972).CrossRefGoogle Scholar
  19. [19]
    A. Doenicke, W. Lorenz, R. Beigl, H. Bezecny, G. Uhlig, L. Kalmar, B. Praetorius andG. Mann,Histamine release after intravenous application of short-acting hypnotics: a comparison of etomidate, althesin (CT 1314) and propanidid, Br. J. Anaesth.45, 1097–1104 (1973).PubMedGoogle Scholar
  20. [20]
    P. Cote, M.G. Bourassa, J. Delaye, A. Janin, R. Froment andP. David,Effects of amiodarone on cardiac and coronary hemodynamic and on myocardial metabolism in patients with coronary artery disease, Circulation59, 1165–1172 (1979).PubMedGoogle Scholar
  21. [21]
    R. Charlier, G. Deltour, A. Baudine andF. Chaillet,Pharmacology of Amiodarone, an antianginal drug with a new biological profile, Arzneimittel-Forsch.18, 1408–1417 (1968).Google Scholar
  22. [22]
    N. El-Sherif, R.R. Hope, B.J. Sherlag andR. Lazzara,Reentrant ventricular arrhythmias in the late myocardial infarction period. 1. Conduction characteristics in the infarction zone, Circulation55, 686–701 (1977).PubMedGoogle Scholar
  23. [23]
    N. El-Sherif, R.R. Hope, B.J. Sherlag andR. Lazzara,Reetrant arrhythmias in the late myocardial infarction period. 2. Patterns of initiation and termination of reentry, Circulation55, 702–719 (1977b).PubMedGoogle Scholar
  24. [24]
    J.T. Bigger, A.L. Basseit andB.F. Hoffman,Electrophysiological effects of diphenylhydantoin on canine Purkinje fibers, Circulation Res.22, 221–236 (1968).PubMedGoogle Scholar
  25. [25]
    W.B. Gough, R.H. Zeiler, P. Barreca andN. El-Sherif,Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs, J. Cardiovasc. Pharmac.4, 375–380 (1982).Google Scholar
  26. [26]
    W. Lorenz, H.J. Reimann, A. Schmal, P. Dormann, B. Schwarz andE. Neugebauer,Histamine release in dogs by Cremophor El ® and its derivatives: oxethylated oleic acid is the most effective constituent, Agents and Actions7, 63–67 (1977).PubMedGoogle Scholar
  27. [27]
    R.S.J. Clarke, J.W. Dundee, T. Garrett, G.K. McArdle andJ.S. Sutton,Adverse reactions to intravenous anaesthetics. Br. J. Anaesth.47, 575–585 (1975).PubMedGoogle Scholar
  28. [28]
    B. Unväs andI.L. Thon,Evidence for enzymatic histamine release from isolated rat mast cells, Expl. Cell. Res.23, 45–57 (1961).CrossRefGoogle Scholar
  29. [29]
    P.A. Shore, A. Burkhalter andV.H. Cohn,A method for the fluorimetric assay of histamine in tissue, J. Pharmac. exp. Ther.127, 182–186 (1959).Google Scholar
  30. [30]
    L.T. Kremzner andI.R. Wilson,A procedure for the determination of histamine, Biochim. biophys. Acta50, 364–367 (1961).CrossRefGoogle Scholar
  31. [31]
    H.U. Bergmeyer andE. Bernt, Lactate dehydrogenase. UV-Assay with pyruvate and NADH. InMethods of Enzymatic Analysis, vol. 2, pp. 574–579 (Ed.H.U. Bergmeyer) Verlag Chemic Academic Press, New York, 1974.Google Scholar
  32. [32]
    W. Lorenz,Histamine release in man, Agents and Actions,5, 402–416 (1975).PubMedGoogle Scholar
  33. [33]
    R.T. Garrett, The clinical manifestations of adverse reactions following althesin and thiopentane. InAdverse Response to Intravenous Drugs, pp. 34–40 (EdsJ. Watkins andA.M. Ward) Academic Press, London 1978.Google Scholar
  34. [34]
    A. Doenicke, Pseudoallergic reactions due to histamine release during intravenous anaesthesia. InPseudoallergic Reactions: Genetic Aspects and Anaphylactoid Reactions, pp. 224–250 (EdsP. Dukor, P. Kallos, H.D. Schlumberger andG.B. West) S. Karger, Basel 1980.Google Scholar
  35. [35]
    J. Watkins,Anaphylactoid reactions to i.v. substances, Br. J. Anaesth.51, 51–60 (1979).PubMedGoogle Scholar
  36. [36]
    W. Lorenz andA. Doenicke, Anaphylactoid reactions and histamine release by intravenous drugs used in surgery and anaesthesia. InAdverse response to Intravenous Drugs, pp. 83–112 (Eds.J. Watkins andA.M. Ward) Academic Press, London 1978.Google Scholar
  37. [37]
    J.B. Glen, G.E. Davies, D.S. Thomson, S.C. Scarth andA.V. Thompson, Adverse reaction to intravenous anaesthetics in animals. InAdverse Response to Intravenous Drugs, pp. 129–135 (Eds.J. Watkin andA.M. Ward) Academic Press, London 1978.Google Scholar
  38. [38]
    J.B. Glen, G.E. Davies, D.S. Thomson, S.C. Scarth andA.V. Thompson,An animal model for the investigation of adverse response to i.v. anaesthetic agents and their solvents, Br. J. Anaesth.51, 819–827 (1978).Google Scholar
  39. [39]
    W. Schmutzler,Histamine release from human adenoidal mast cells induced by anti-human IgE, acetylcholine Epontol ®,Chremophor El ® and 12-hydroxystearic acid, Allergologie, in press.Google Scholar
  40. [40]
    M. Werner andE. Wolff, Klinisch-experimentelle Untersuchungen zur Frage der Propanidid-Allergie. In (EdsM. Zindler, H. Yamamura, W. Wirth) Springer-Verlag, Heidelberg, New York 1973).Google Scholar
  41. [41]
    M. Thermann, W. Lorenz, A. Schmal, F. Schingale, P. Dormann andH. Hamelmann Alterations in the circulatory system of anaesthetized dogs following administration of histamine and histamine H 1-and H 2-receptor antagonists in relation to plasma histamine levels, Agents and Actions5, 450–455 (1975).PubMedGoogle Scholar
  42. [42]
    S.C. Verma andJ.H. McNeill Cardiac histamine receptors: differences between right and left atria and right ventricle, J. Pharmac. exp. Ther.200, 352–362 (1977).Google Scholar
  43. [43]
    R. Ginsburg, M.R. Bristow andE.B. Stinson,Histamine receptors in the human heart, Life Sci.26, 2245–2249 (1980).CrossRefPubMedGoogle Scholar
  44. [44]
    J. Moss, N.R. Fahmy, N. Sunder andM.A. Beaven,Hormonal and hemodynamic profile of an anaphylactic reaction in man, Circulation63, 210–213 (1981).PubMedGoogle Scholar
  45. [45]
    W. Lorenz, R. Meyer, A. Doenicke, A. Schmal, H.J. Reimann, M. Hutzel andE. Werle,On the species specificity of the histamine release from mast cell stores by Cremophor El ®, Naunyn-Schmiedeberg's Arch. Pharmak.269, 417–421 (1971).Google Scholar

Copyright information

© Birkhäuser Verlag 1985

Authors and Affiliations

  • Emanuela Masini
    • 1
  • Jaques Planchenault
    • 2
  • Francis Pezziardi
    • 2
  • Patrick Gautier
    • 2
  • Jean Pierre Gagnol
    • 2
  1. 1.Department of Preclinical and Clinical PharmacologyUniversity of FlorenceFirenzeItaly
  2. 2.Sanofi-Centre de Recherches Clin-MidyMontpellier CedexFrance

Personalised recommendations